The Economic Survey 2024-25 reveals an expected increase in Goa's population to 15.96 lakh by 2025 but highlights worrying ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

Did you know people with diabetes are twice as likely to develop heart disease compared to those without diabetes?

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...

Heart disease is the leading cause of death among women, yet many miss the early warning signs due to subtle or atypical ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

While the typical image of someone suffering a heart attack might be a man clutching his chest, heart disease is a major ...